NCT07641634招募中1 期
A Two-part, Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study of PRO-203 in Healthy Adult Volunteers Followed by an Open-label, Single-ascending-dose With Priming Study of PRO-203 in Participants With Systemic Sclerosis
Prolium Bioscience, Inc11 个研究点 分布在 4 个国家目标入组 44 人开始时间: 2025年10月27日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 44
- 试验地点
- 11
研究概览
简要总结
A two-part study of PRO-203 administered subcutaneously in healthy adult volunteers and participants with Systemic Sclerosis (SSc).
详细描述
This two-part study is designed to characterize the first-in-human safety, tolerability, PK, and PD profile of PRO-203 across ascending dose levels.
Part 1 - Healthy Volunteers (HV) Part 1 enrollment is complete and has enrolled 20 healthy volunteers across 3 cohorts. Participants within each cohort received a single SC dose of PRO-203 or matching placebo. Part 1 has completed enrollment.
Part 2 - Systemic Sclerosis (SSc) Up to 24 participants with SSc will be enrolled in multiple cohorts (with optional additional cohorts) Participants within each cohort will receive a single SC cycle of PRO-203. Part 2 includes a Main Study and an optional Long-term Extension (LTE). In the LTE, eligible participants may receive retreatment if they meet retreatment criteria. Total study duration per participant is up to 53 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Double (Participant, Investigator) - Part 1 only; Open Label - Part 2
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(All Participants)
- •Is male or female, age 18 to 65 years, inclusive, at Screening.
- •Able to provide Informed Consent.
- •Absolute B cell count > 25 cells/uL.
- •Additional Inclusion for Part 1 (Closed to Enrollment)
- •In good general health, determined by no clinically significant findings in the of the investigator from medical history, physical examination, 12-lead ECG, clinical laboratory findings, and vital signs at Screening and Day -1 (participants with Gilbert's disease with associated abnormalities of liver function tests are eligible for enrollment).
- •Up to date vaccination status per local guidelines (including but not limited to influenza vaccine, COVID booster and hepatitis B vaccine).
- •Additional Inclusion for Part 2
- •Fulfill 2013 ACR/ EULAR criteria for classification of SSc with a total score of ≥
- •Active disease defined as at least two of the following at screening:
- •Disease duration ≤ 2 years (since onset of first-non-Raynaud-symptom), or
- •Elevated acute phase reactant levels (CRP ≥ 6 mg/L, erythrocytes sedimentation rate [ESR] ≥ 28 mm/1h, or platelet count ≥ 330,000/µL), or
- •Baseline mRSS ≥10 with evidence of progression, defined as mRSS increase at least 3 units, or involvement of 1 new body area and mRSS increase at least 2 units, or involvement of 2 new body areas (each within the previous 6 months), or
- •≥ 1 tendon friction rub, or
- •Elevation of CK or aldolase > 2 × the upper limit of normal (ULN) consistent with SSc-related myopathy, or
- •Progressive fibrosing interstitial lung disease (ILD) as defined by at least one of the following criteria at any time within the prior 2 years:
- •relative decline in forced vital capacity (FVC) % predicted ≥ 10%, or
- •relative decline in FVC % predicted ≥ 5% to <10% and worsened respiratory symptoms, or
- •relative decline in FVC % predicted ≥ 5% to <10% and increased extent of fibrosis on high-resolution computed tomography (HRCT), or
- •worsened respiratory symptoms and increased extent of fibrosis on HRCT
- •Intolerant or refractory to at least 1 line of standard therapy, including methotrexate, azathioprine, IVIG, mycophenolic acid derivatives, cyclophosphamide, TNF-inhibitors, rituximab, or tocilizumab.
排除标准
- •(All Participants)
- •Any clinically significant underlying illness in the opinion of the investigator.
- •Active infection within 4 weeks prior to screening. Participants receiving IV antibiotics or having received IV antibiotics within 14 days prior to enrollment are excluded.
- •Positive QuantiFERON-Gold TB test at screening.
- •Plan to receive live, attenuated vaccine after signing ICF (inactive vaccines, such as the flu vaccine, are allowed).
- •Evidence of malignant disease or malignancies diagnosed within the previous 5 years (except for treated local basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that had been excised and cured).
- •Currently enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives of the prior investigational agent (whichever is longer) have passed since ending another investigational device or drug study or plans to enroll in another investigational device or drug study during the course of this study.
- •Social smokers e.g. up to 10 cigarettes per week (or equivalent amounts of nicotine containing products) and willing to abstain during inpatient stay, are allowed
- •Additional Exclusion Criteria for Part 1 (Closed to Enrollment)
- •Use of any prescription medication within 14 days and OTC medications, vitamins, herbal medications (e.g., St. John's wort), or cannabis, except for contraceptive medications and as needed (prn) acetaminophen/paracetamol (not exceeding 2 grams/day) within 7 days prior to administration of the study drug and throughout the study.
- •Additional Exclusion Criteria for Part 2
- •Rheumatic autoimmune disease other than SSc.
- •Positive anti-centromere antibodies.
- •Pulmonary disease with FVC ≤ 45% of predicted, or DLCO ≤ 35% of predicted.
- •Class 2 or higher pulmonary arterial hypertension or evidence of other moderately severe pulmonary disease.
- •Renal crisis within 6 months prior to Screening.
- •Prior treatment with cellular immunotherapy (eg, CAR-T) or gene therapy product directed at any target.
- •Previous treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation.
- •Previous treatment with thalidomide, anti-thymocyte globulin, plasmapheresis, or extracorporeal photopheresis.
- •Unable to washout current immunosuppressive therapy within 2 months
- •Has received anti-CD19 or CD20 therapies, within 6 months prior to start of therapy
- •Plan to receive live or live-attenuated vaccines within 8 weeks prior to first dose of study drug and during treatment until B cell reconstitution to 80% of baseline (inactive vaccines, such as the flu vaccine, are allowed)
研究组 & 干预措施
Part 1: Placebo
Placebo Comparator
Matching SC placebo administered to randomized Part 1 participants
干预措施: Placebo (Other)
Part 2: Multiple Doses of PRO-203
Experimental
Participants with systemic sclerosis receive a single cycle of PRO-203 across cohorts, including additional treatment as needed.
干预措施: PRO-203 (Drug)
Part 1: PRO-203
Experimental
Healthy participants receive single ascending dose of PRO-203 in dose escalation cohorts
干预措施: PRO-203 (Drug)
研究者
研究点 (11)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate ALN-2232 in Participants With ObesityObesityNCT07463846Alnylam Pharmaceuticals156
已完成
1 期
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive EpisodeMajor Depressive Disorder (MDD)SchizophreniaBipolar DisorderNCT07549581Otsuka Pharmaceutical Development & Commercialization, Inc.43
已完成
1 期
A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.NCT07575906Pfizer8
尚未招募
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Gastrodin Injection in Healthy Chinese SubjectsDeliriumNCT07422142Kunming Pharmaceuticals, Inc.54
招募中
1 期
A First-in-human Trial of GRT7041 in Healthy ParticipantsNCT07289776Grünenthal GmbH70